What we do
Stemina is the world leader in building human cellular models for toxicity screening of drug candidates, chemical compounds, cosmetic and tobacco ingredients. Our developmental toxicity assays are the only human system for assessing the risk that a compound will cause birth defects if a woman is exposed during pregnancy.
MORE ABOUT US

What we do

Toxicology

Stemina's toxicology assays are the only human in vitro assays for developmental toxicity screening.

LEARN MORE

Technologies

Stemina's metabolomics platform and expertise in cellular models can be used for custom projects.

LEARN MORE

Our Team

Stemina has assembled a world class team of scientists and experts. Meet our team.

LEARN MORE

Latest news

Jun 15

Stemina to Present Poster at Teratology Society Annual Meeting

Jun 15, 2018
Stemina’s Jessica Palmer to Present Poster at Teratology Society Annual Meeting Jessica Palmer, Stemina’s Associate Director of Toxicology, will present a poster at the Teratology Society Annual Meeting, held June 23-27, 2018 in Clearwater, Florida. Anyone interested in developmental toxicity assays is encouraged to attend. A Human Pluripotent Stem Cell-Based Assay Accurately Predicts the Developmental

Read more
Feb 20

Stemina Launches Cardiotoxicity Assay, Presents Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2018

Feb 20, 2018
Stemina Launches Cardiotoxicity Assay, Presents Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2018 The Stemina team will attend the Society of Toxicology’s Annual Meeting and ToxExpo in San Antonio, Texas from March 11-15, 2018. We are excited to share information about our new cardiotoxicity assay, Cardio quickPredict, now commercially-available for the first time.

Read more
Jan 18

NeuroPointDX Announces Validation of First-Generation Autism Diagnostic Panel

Jan 18, 2018
NeuroPointDX, the neurodevelopmental disorders division of Stemina Biomarker Discovery, has validated 12 metabolic subtypes of autism spectrum disorder. The diagnostic blood test for ASD will be available later this year. CEO Elizabeth Donley says, “This is a historic moment, not just for Stemina and NeuroPointDX, but for our knowledge and understanding of autism.” Read the

Read more